Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · HARVARD BIOSCIENCE INC (HBIO)

Harvard Bioscience Q2 revenue rises 11% to $22.7M; FY26 revenue outlook raised

Mixed Impact 3 of 5 earnings Written later

Harvard Bioscience furnished an August 2026 investor presentation under Regulation FD showing second-quarter 2026 revenue of $22.7 million, up 11% from $20.5 million a year earlier. The company raised its full-year 2026 revenue growth guidance to 3% to 5% from 2% to 4%, but lowered its adjusted gross margin guidance to 57% to 59% from 58% to 60%. GAAP net loss widened to $2.9 million from $2.3 million, while adjusted EBITDA rose to $1.7 million from $1.5 million.

Key points

  • Q2 2026 revenue of $22.7 million, up from $20.5 million in Q2 2025
  • GAAP net loss of $2.9 million, compared with $2.3 million a year earlier
  • Adjusted EBITDA of $1.7 million, up from $1.5 million; adjusted EBITDA growth guidance for FY26 maintained at 6% to 10%
  • Q3 2026 revenue guidance of $21.0 million to $22.6 million

The filing

CompanyHARVARD BIOSCIENCE INC (HBIO)
Form8-K, current report
Filed with the SECAug 11, 2026, 7:00 AM ET
Accession number0001171843-26-005406

Items reported: 7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:36 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 11, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.